Haimanot Wasse

Haimanot Wasse

Auto-generated profile, based on publicly available information

Haimanot Wasse

Rush University Medical Center, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
LGLeila Bertoni Giron
Leila Bertoni Giron
MPMichael J. Peluso
Michael J. Peluso
JDJianyi Ding
Jianyi Ding
GKGrace Kenny
Grace Kenny
NZNetanel F. Zilberstein
Netanel F. Zilberstein
MAMohamed Abdel-Mohsen
Mohamed Abdel-Mohsen
Long COVID, a type of post-acute sequelae of SARS-CoV-2 (PASC), has been associated with sustained elevated levels of immune activation and inflammation. However, the mechanisms that drive this inflammation remain unknown. Inflammation during acute coronavirus disease 2019 could be exacerbated by microbial translocation (from the gut and/or lung) to blood. Whether microbial translocation contributes to inflammation during PASC is unknown. We did not observe a significant elevation in plasma markers of bacterial translocation during PASC. However, we observed higher levels of fungal translocation — measured as β-glucan, a fungal cell wall polysaccharide — in the plasma of individuals experiencing PASC compared with those without PASC or SARS-CoV-2–negative controls. The higher β-glucan correlated with higher inflammation and elevated levels of host metabolites involved in activating N -methyl-d-aspartate receptors (such as metabolites within the tryptophan catabolism pathway) with established neurotoxic properties. Mechanistically, β-glucan can directly induce inflammation by binding to myeloid cells (via Dectin-1) and activating Syk/NF-κB signaling. Using a Dectin-1/NF-κB reporter model, we found that plasma from individuals experiencing PASC induced higher NF-κB signaling compared with plasma from negative controls. This higher NF-κB signaling was abrogated by piceatannol (Syk inhibitor). These data suggest a potential targetable mechanism linking fungal translocation and inflammation during PASC.

27 February 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
SSSurendra Shenoy
Surendra Shenoy
MAMichael Allon
Michael Allon
GBGerald Beathard
Gerald Beathard
DBDeborah Brouwer-Maier
Deborah Brouwer-Maier
LDLaura M. Dember
Laura M. Dember
HWHaimanot Wasse
Haimanot Wasse

29 November 2019 in The Journal of Vascular Access
Verified
Journal Article
Closed access
PDF file
HWHaimanot Wasse
Haimanot Wasse
AAAlejandro C Alvarez
Alejandro C Alvarez
DBDebbie Brouwer-Maier
Debbie Brouwer-Maier
JHJeffrey E Hull
Jeffrey E Hull
SBSaravanan Balamuthusamy
Saravanan Balamuthusamy
WJWilliam C Jennings
William C Jennings
End-stage kidney disease patients who are candidates for surgical arteriovenous fistula creation commonly experience obstacles to a functional surgical arteriovenous fistula, including protracted wait time for creation, poor maturation, and surgical arteriovenous fistula dysfunction that can result in significant patient morbidity. The recent approval of two endovascular devices designed to create a percutaneous arteriovenous fistula enables arteriovenous fistula creation to be placed in the hands of interventionalists, thereby increasing the number of arteriovenous fistula providers, reducing wait times, and allowing the patient to avoid surgery. Moreover, current studies demonstrate that patients with percutaneous arteriovenous fistula experience improved time to arteriovenous fistula maturation. Yet, in order to realize the potential advantages of percutaneous arteriovenous fistula creation within our hemodialysis patient population, it is critical to select appropriate patients, ensure adequate patient and dialysis unit education, and provide sufficient instruction in percutaneous arteriovenous fistula cannulation and monitoring. In this White Paper by the American Society of Diagnostic and Interventional Nephrology, experts in interventional nephrology, surgery, and interventional radiology convened and provide recommendations on the aforementioned elements that are fundamental to a functional percutaneous arteriovenous fistula.

27 June 2020 in The Journal of Vascular Access
Verified
Journal Article
Open access
PDF file
MRMahmood K Razavi
Mahmood K Razavi
EPEric K Peden
Eric K Peden
ESEhab Sorial
Ehab Sorial
JRJohn R Ross
John R Ross
JAJohn E Aruny
John E Aruny
ZHZiv J Haskal
Ziv J Haskal
Thoracic central venous obstruction is commonly associated with the use of central venous catheters. The Surfacer System to Facilitate Access in Venous Occlusions Study was an Food and Drug Administration–approved US Investigational Device Exemption study designed to evaluate the performance and safety of the Surfacer System when used to facilitate central venous access in patients with thoracic central venous obstruction. Thirty patients were enrolled in this prospective, multicenter, single-arm study between December 2017 and May 2019. Device performance and adverse events were collected peri-procedurally and at discharge. Enrollment included 15 female and 15 male subjects with a mean age of 55.5 ± 12.9 (range: 30–79) years. Twenty-eight patients (93.3%) required central venous access for hemodialysis access. Locations of thoracic central venous obstruction were graded from 1 to 4 based on severity and extension of venous occlusions. Seven patients (23.3%) had type 1, 6 (20.0%) type 2, 16 (53.3%) type 3, and 1 (3.3%) type 4 obstruction. Successful central venous catheter placement was achieved in 27 of 30 patients (90.0%). The procedure was discontinued in three (10.0%) due to tortuous anatomy discovered intraprocedurally. All 27 patients with successful CVC placement achieved adequate catheter patency and tip positioning with a mean overall procedural time and time to achieve central venous access with the Surfacer System being 44.1 ± 30.6 and 19.1 ± 25.1 min, respectively. There were no device-related adverse events or catheter malposition. The results of the SAVEUS Study confirm the safety and efficacy of the Surfacer System and the Inside-Out procedure when used for the placement of right-sided central venous access in patients with thoracic central venous obstruction.

30 December 2019 in The Journal of Vascular Access
Verified
Journal Article
Open access
PDF file
GBGerald A Beathard
Gerald A Beathard
WJWilliam C Jennings
William C Jennings
HWHaimanot Wasse
Haimanot Wasse
SSSurendra Shenoy
Surendra Shenoy
DHDirk M Hentschel
Dirk M Hentschel
AAArif Asif
Arif Asif
Although not common, hemodialysis access-induced distal ischemia is a serious condition resulting in significant hemodialysis patient morbidity. Patients with signs and symptoms suggestive of hand ischemia frequently present to the general and interventional nephrologist for evaluation. In order to care for these cases, it is necessary to understand this syndrome and its management. Most cases can be managed conservatively without intervention. Some cases requiring intervention may be treated using techniques within the scope of practice of the interventional nephrologists while other cases require vascular surgery. In order for the interventional nephrologists to evaluate and manage these cases in a timely and appropriate manner, practice guidelines are presented.

10 July 2013 in The Journal of Vascular Access
Verified
Journal Article
Open access
HWHaimanot Wasse
Haimanot Wasse
RHRong Huang
Rong Huang
QLQi Long
Qi Long
YZYize Zhao
Yize Zhao
SSSalman Singapuri
Salman Singapuri
Vin TangprichaVin Tangpricha
Vin Tangpricha
Purpose: While vitamin D is critical for optimal skeletal health, it also appears to play a significant role in vascular homeostasis. This pilot study compared arteriovenous (AV) access outcomes following cholecalciferol supplementation compared to placebo in end-stage renal disease patients preparing to undergo AV access creation. Methods: A total of 52 adult hemodialysis patients preparing for arteriovenous fistula (AVF) creation were randomized to receive perioperative high-dose cholecalciferol versus placebo in this double-blind, randomized, placebo-controlled pilot study. The primary outcome was mean response to high-dose oral cholecalciferol versus placebo, and secondary outcome AV access maturation at 6 months. Logistic regression was used to assess the association between AV access maturation and baseline, posttreatment and overall change in vitamin D concentration. Results: A total of 45% of cholecalciferol-treated and 54% of placebo-treated patients were successfully using their AVF or arteriovenous graft (AVG) at 6 months (p=0.8). Baseline serum concentrations of 25(OH)D and 1,25(OH)2D did not differ between those who experienced AVF or AVG maturation and those who did not (p=0.22 and 0.59, respectively). Similarly, there was no relationship between AVF or AVG maturation and posttreatment serum 25(OH)D and 1,25(OH)2D concentration (p=0.24 and 0.51, respectively). Conclusions: Perioperative high-dose vitamin D3 therapy does correct 25(OH)D level but does not appear to have an association with AV access maturation rates. Future research may include extended preoperative vitamin D3 therapy in a larger population or in certain subpopulations at high risk for AVF failure.